Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,011 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Drug 4 mL: Clear all
Completed Phase 3 Interventional Results available

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

NCT03959241
View directory record Official record
Conditions
Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia, Lymphoma
Interventions
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, Tacrolimus, Methotrexate, Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide, Mycophenolate Mofetil, Cyclophosphamide
Procedure · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Analysis of Atropine and Propranolol Induced Changes

NCT00251602
View directory record Official record
Conditions
Healthy
Interventions
Atropine, Propranolol, Normal Saline
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Not applicable Interventional Results available

Role of Endorphins in Perception of Dyspnea With Resistive Loading in Chronic Obstructive Pulmonary Disease (COPD)

NCT00958919
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
naloxone, normal saline
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
50 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 2 Interventional Results available

Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension

NCT01682837
View directory record Official record
Conditions
Hypertension
Interventions
Potassium chloride powder, Potassium citrate powder, Potassium magnesium citrate powder, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 20, 2026, 6:15 PM EDT
Terminated Phase 1 Interventional

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

NCT00238173
View directory record Official record
Conditions
Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Long-term Effects Secondary to Cancer Therapy in Children
Interventions
filgrastim, acetylcysteine, carboplatin, cyclophosphamide, etoposide phosphate, mannitol, sodium thiosulfate
Biological · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
1 Year to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 20, 2026, 6:15 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

NCT03970447
View directory record Official record
Conditions
Glioblastoma
Interventions
Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine
Drug · Radiation · Biological
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years and older
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
42
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Staccato® Granisetron Single Dose PK

NCT04200092
View directory record Official record
Conditions
Healthy
Interventions
0.5mg AZ-010; placebo, 1mg AZ-010, 3mg AZ-010, AZ-010 1mg, IV Granisetron 1mg, Placebo
Combination Product · Drug · Other
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Testing the Feasibility of Patient Controlled Sedation for Ventilated ICU Patients

NCT01606852
View directory record Official record
Conditions
Acute Respiratory Failure, Anxiety
Interventions
Dexmedetomidine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study of Substance P-Saporin in Terminal Cancer Patients With Intractable Pain

NCT02036281
View directory record Official record
Conditions
Terminally Ill, Histologically-confirmed Advanced Cancer, Pain, Intractable
Interventions
Substance P-Saporin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
La Jolla, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 2 Interventional

Investigator-Sponsored Protocol - Continued Use of Ibalizumab

NCT01056393
View directory record Official record
Conditions
HIV Infections
Interventions
ibalizumab 800mg Q2Weeks, ibalizumab 2000mg Q4Weeks
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis

NCT04304144
View directory record Official record
Conditions
AL Amyloidosis
Interventions
CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Stanford, California • Detroit, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 2 Interventional Results available

Investigation of Mesenchymal Stem Cell Therapy for the Treatment of Osteoarthritis of the Knee

NCT02958267
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
BMAC injection, PRP injection, Gel-One® hyaluronate injection
Biological · Device
Lead sponsor
OhioHealth
Other
Eligibility
40 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 20, 2026, 6:15 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Repeat Antenatal Steroids Trial

NCT00015002
View directory record Official record
Conditions
Complications, Pregnancy
Interventions
Betamethasone
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
486 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2007
U.S. locations
19
States / cities
Birmingham, Alabama • Miami, Florida • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 20, 2026, 6:15 PM EDT
Recruiting Phase 2 Interventional

ELISA in Relapsed/Refractory MM

NCT06832865
View directory record Official record
Conditions
Relapsed Refractory Multiple Myeloma (RRMM), Relapsed Refractory Multiple Myeloma
Interventions
elranatamab, Isatuximab SC, Isatuximab SC-OBDS
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 20, 2026, 6:15 PM EDT
Withdrawn Phase 2 Interventional

Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer

NCT01830322
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
CPI-613, Gemcitabine, Any non-gemcitabine chemotherapies or best supportive care
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
The Bronx, New York • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Oct 20, 2026, 6:15 PM EDT
Terminated Phase 2 Interventional Results available

Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer

NCT00216086
View directory record Official record
Conditions
Rectal Cancer
Interventions
Capecitabine, Irinotecan, EUS, Neoadjuvant Chemotherapy, Preoperative Radiation, Surgery, Adjuvant Chemotherapy
Drug · Procedure
Lead sponsor
Gabi Chiorean, MD
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Elkhart, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 2 Interventional Results available

Trial of NanoPac Intratumoral Injection in Lung Cancer

NCT04314895
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell, Lung Cancer, Lung Cancer, Small Cell, Neoplasm of Lung
Interventions
NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
Drug
Lead sponsor
NanOlogy, LLC
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Gainesville, Florida • Fort Wayne, Indiana • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 20, 2026, 6:15 PM EDT
Recruiting Phase 3 Interventional

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

NCT05902169
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, GBM
Interventions
SonoCloud-9 (SC9), Carboplatin, Lomustine, Temozolomide
Device · Drug
Lead sponsor
CarThera
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal

NCT01759394
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Avatrombopag maleate 40 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)

NCT04283461
View directory record Official record
Conditions
COVID-19, COVID-19 Immunisation
Interventions
mRNA-1273
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Decatur, Georgia • Bethesda, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 20, 2026, 6:15 PM EDT
Active, not recruiting Phase 2 Interventional

Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD

NCT05621759
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Cyclophosphamide, Abatacept, Tacrolimus
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Not applicable Interventional

Contingency Management and Pharmacotherapy for Smoking Cessation

NCT00683280
View directory record Official record
Conditions
Cigarette Smoking
Interventions
contingency management, Standard of Care
Behavioral · Other
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 2 Interventional Results available

Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head & Neck Cancer

NCT01653327
View directory record Official record
Conditions
Mucositis, Head and Neck Cancer
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 20, 2026, 6:15 PM EDT
Completed Phase 4 Interventional

Genicular and Anterior Femoral Cutaneous Nerve Blocks for Total Knee Arthroplasty

NCT05980546
View directory record Official record
Conditions
Total Knee Replacement, Genicular Nerve Block, Opioid Use
Interventions
Bupivacaine Injection, Dexamethasone injection, Fentanyl, Mepivacaine
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 20, 2026, 6:15 PM EDT